Prognostic Role Of Advanced Glycation End Products In Male Patients With Obstructive Sleep Apnoea Syndrome And Hypertension

Increased advanced glycation end products (AGE) levels have been reported in diabetes mellitus, obstructive sleep apnoea syndrome (OSAS) or hypertension patients. However, it remain unclear its prognosis value in OSAS patients with hypertension. In this study, we tried to explore the role of AGE in prognosis of OSAS patients with hypertension. 68 male OSAS patients (27 patients with hypertension, 41 patients without hypertension), 19 male control subjects were admitted. The major cardio-cerebral vascular event (MACCE) in OSAS patients were recorded in the 24-months' follow-up. There was no significant difference in ages, BMI, pack-years of smoking between, neck circumference and abdominal circumference in the three groups. The AHI and serum AGE levels of OSAS patients with hypertension were both significantly higher than controls group and OSAS without hypertension group. Moreover, the MACCE subjects were older and had higher levels of cholesterol and hs-CRP when comparing with non-MACCE subjects in OSAS patients. The MACCE subjects also had lower levels of lowest SpO(2), higher levels of AHI and serum AGE as compared with non-MACCE subjects. Serum AGE levels was negatively associated with lowest SpO(2), and positively correlated with AHI as well as hs-CRP. Multiple logistic regression analysis showed that serum AGE levels, AHI and lowest SpO(2) were independently associated with MACCE in 24 months. So, we concluded that serum AGE played a prognostic role in patients with OSAS and hypertension.